Ballentine Partners’s BeOne Medicines ONC Stock Holding History
Bought
Maintained
Sold
Other funds holding ONC
BBA
Ballentine Partners's ONC Position: Q3 2026 in Review
Ballentine Partners increased its BeOne Medicines (ONC) stake by 50% in Q3 2026, buying an estimated $169K and bringing the position to 1,481 shares worth $542K. The position accounts for 0.01% of the portfolio, ranked #559.
Ballentine Partners first reported a position in ONC in Q3 2025 and has held it in 5 quarters since. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.
- Ballentine Partners held 1,481 shares of BeOne Medicines worth $542K as of Q3 2026.
- Ballentine Partners bought 493 BeOne Medicines shares in Q3 2026, an estimated $169K.
- BeOne Medicines made up 0.01% of Ballentine Partners's portfolio in Q3 2026, its #559 holding.
- Ballentine Partners first reported a position in BeOne Medicines in Q3 2025 and has held it in 5 quarters since.
- 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.
Based on Ballentine Partners's 13F filing for Q3 2026, filed 13 Nov 2026.